27 November 2017Big Pharma

MSD launches UK hub as government announces industrial strategy

MSD, known as Merck and Co in the US and Canada, announced plans to launch a life sciences discovery research facility just hours ahead of the UK government’s release of its industrial strategy.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

UK government announces life sciences deal; GSK and AstraZeneca invest

11 December 2017 The UK government has announced a deal between the life sciences sector and the government, aimed at ensuring that the “next wave of breakthrough treatments” and innovative medical research and technologies are created in the country.

Europe

Regeneron forms consortium to fund exome sequencing

12 January 2018 Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.

Big Pharma

UKIPO issues formal response to Industrial Strategy IP views

22 May 2018 The UK Intellectual Property Office has published several proposals, including some addressing barriers to growth for IP-rich companies, in response to received views of IP with regard to the government’s Industrial Strategy.

More on this story

Big Pharma

UK government announces life sciences deal; GSK and AstraZeneca invest

Europe

Regeneron forms consortium to fund exome sequencing

12 January 2018 Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.

Big Pharma

UKIPO issues formal response to Industrial Strategy IP views

More on this story

Big Pharma

UK government announces life sciences deal; GSK and AstraZeneca invest

Europe

Regeneron forms consortium to fund exome sequencing

12 January 2018 Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.

Big Pharma

UKIPO issues formal response to Industrial Strategy IP views